comparemela.com

Latest Breaking News On - Tungsten partners - Page 1 : comparemela.com

First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company

Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal disease clinical pipeline A concurrent institutional.

Boca ratonUnited statesJames sapirsteinChaitan khoslaJack syageDavid schemeliaCompany annual report on formDrug administrationFirst wave biopharma incFirst wave bio incTungsten partnersFinalis securitiesImmunogenx incTiberend strategic advisors incStanford universityExchange commission

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

CINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) Blue Water Biotech, Inc. (Nasdaq: BWV) ( BWB or the “Company”) today announced the acquisition of.

United statesNic johnsonNeilj campbellHarrison seidnerTungsten partnersFinalis securitiesBlue water biotech incOnconetix incRusso partnersWater biotechBlue water biotechProstate specific antigenTungsten advisorsMedia contact information

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™ - Blue Water Biotech (NASDAQ:BWV)

CINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) Blue Water Biotech, Inc. (NASDAQ:BWV) ("BWB" or the "Company") today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology

United statesNeilj campbellHarrison seidnerNic johnsonTungsten partnersFinalis securitiesBlue water biotech incRusso partnersOnconetix incWater biotechBlue water biotechProstate specific antigenTungsten advisorsMedia contact information

Proteomedix Agrees to Issue Labcorp Exclusive License for Proclarix Blood Test to Detect Prostate Cancer

Labcorp Plans to Develop and Commercialize the Innovative Prostate Cancer Liquid Biopsy Test in the U.S. Proteomedix, a Swiss diagnostics company committed to advancing prostate cancer care, announced

United statesUnited kingdomGewinn nurBrown rudnickHelge lubenowPrasanth reddyTungsten partnersFinalis securitiesLabcorp plansInnovative prostate cancer liquid biopsy testSpecific antigenTungsten advisors

MolecuLight Inc : MolecuLight Secures Financing from BDC Canada and iGan Partners to Support its Commercial Expansion

New Financing to Meet Significant Growth in Global Demand for MolecuLight's i:X and DX Point-of-Care Imaging Devices for the Wound Care Industry TORONTO, Aug. 11, 2022 /PRNewswire/ MolecuLight

United statesKostenloser wertpapierhandelRob sandlerSam iferganLeonard kofmanJody staggsFinalis securitiesSurgical centerTungsten partnersMoleculight incPrnewswire moleculight incHospital outpatient departmentNew financingMeet significant growthGlobal demandCare imaging devices

vimarsana © 2020. All Rights Reserved.